Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) Latest Company News

Sep 14, 2026, 08:55 UTC
Zhejiang Hisun Animal Health Products, a controlled subsidiary of Hisun Pharmaceutical, received approval from the Ministry of Agriculture and Rural Affairs for a compound fipronil-praziquantel-moxidectin spot-on veterinary drug product, valid from September 10, 2026 to September 9, 2031.
Source:
- finance.sina.cn
Sep 7, 2026, 08:42 UTC
Hisun Pharmaceutical's subsidiary Zhejiang Hisun Animal Health Products received a new veterinary drug registration certificate for a compound fipronil/praziquantel/moxidectin drop product for cats, and the product is ready for production and market launch.
Source:
- finance.sina.cn
Aug 28, 2026, 02:52 UTC
Hisun Pharmaceutical signed a strategic cooperation agreement with Chengdu Xingji Space Exploration Technology Co., Ltd. (Xingji Development) to enter the space biopharmaceutical sector.
Source:
- finance.sina.cn
Aug 25, 2026, 09:45 UTC
Hisun Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 636 million yuan, up 112.82% year-on-year, with revenue of 4.475 billion yuan, down 14.76%.
Source:
- finance.sina.cn
- wap.eastmoney.com
Aug 18, 2026, 20:30 UTC
Chinese companies, including Fosun Pharma and Zhejiang Hisun Pharmaceutical, expressed interest in expanding partnerships with Jordan in pharmaceutical and food manufacturing, including joint ventures and R&D, during a meeting with King Abdullah in Shanghai.
Source:
- jordantimes.com
Aug 3, 2026, 07:32 UTC
Hisun Pharmaceutical and its wholly-owned subsidiary Hanhui Pharmaceutical participated in the bidding for the 12th national centralized drug procurement on July 31, 2026, with 5 products preliminarily selected, including imipenem and cilastatin sodium for injection, with procurement cycles lasting until December 31, 2029.
Source:
- finance.sina.cn
Jul 3, 2026, 10:31 UTC
Zhejiang Hisun Pharmaceutical Co., Ltd. signed an exclusive license and cooperation agreement with Atia to develop, register, manufacture and commercialize the innovative chemical drug TISA-818 systemic formulation in Mainland China, Hong Kong and Macau.
Source:
- finance.sina.cn
- finance.sina.cn

600267.SH

Zhejiang Hisun Animal Health Products, a controlled subsidiary of Hisun Pharmaceutical, received approval from the Ministry of Agriculture and Rural Affairs for a compound fipronil-praziquantel-moxidectin spot-on veterinary drug product, valid from September 10, 2026 to September 9, 2031.

Hisun Pharmaceutical's subsidiary Zhejiang Hisun Animal Health Products received a new veterinary drug registration certificate for a compound fipronil/praziquantel/moxidectin drop product for cats, and the product is ready for production and market launch.

Hisun Pharmaceutical signed a strategic cooperation agreement with Chengdu Xingji Space Exploration Technology Co., Ltd. (Xingji Development) to enter the space biopharmaceutical sector.

Hisun Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 636 million yuan, up 112.82% year-on-year, with revenue of 4.475 billion yuan, down 14.76%.

Chinese companies, including Fosun Pharma and Zhejiang Hisun Pharmaceutical, expressed interest in expanding partnerships with Jordan in pharmaceutical and food manufacturing, including joint ventures and R&D, during a meeting with King Abdullah in Shanghai.

Zhejiang Hisun Pharmaceutical Co., Ltd. signed an exclusive license and cooperation agreement with Atia to develop, register, manufacture and commercialize the innovative chemical drug TISA-818 systemic formulation in Mainland China, Hong Kong and Macau.